Johnson et al. noted exacerbations of rheumatoid arthritis and inflammatory bowel disease (IBD), as well as increased occurrence of IRAE, during anti-CTLA-4 monotherapy [7]. Here, CTLA4 is linked to inflammatory bowel disease.